HLB Life Science Co Ltd
Korea ExchangeTotal Valuation
HLB Life Science Co Ltd carries a market capitalization of - -, placing it among publicly traded companies globally. Its enterprise value stands at 144.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | - - |
| Enterprise Value | 144.70B |
Share Statistics
HLB Life Science Co Ltd currently has 121.85M shares outstanding.
| Shares Outstanding | 121.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 2.81 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 16.39 |
Financial Position
HLB Life Science Co Ltd maintains a current ratio of 0.55, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.81, indicating elevated leverage, while an interest coverage ratio of -1.78 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.55 |
| Quick Ratio | 0.15 |
| Debt / Equity | 55.81 |
| Debt / EBITDA | -7.52 |
| Interest Coverage | -1.78 |
Financial Efficiency
| Return on Equity (ROE) | -488.50 |
| Return on Assets (ROA) | -10.17 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 8.19 |
Taxes
| Income Tax | 356.70M |
| Effective Tax Rate | N/A |
Stock Price Statistics
HLB Life Science Co Ltd's stock has declined approximately -12.45136% over the past 52 weeks. The 50-day moving average sits at 10,283.60, while the 200-day moving average is 10,754.95.
| Beta (5Y) | N/A |
| 52-Week Price Change | -12.45136% |
| 50-Day Moving Average | 10,283.60 |
| 200-Day Moving Average | 10,754.95 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, HLB Life Science Co Ltd generated 51.51B in revenue and converted that into -50.45B in net income, yielding earnings per share of -414.86. EBITDA reached -21.81B, while operating income came in at -21.81B.
| Revenue | 51.51B |
| Gross Profit | -1.45B |
| Operating Income | -21.81B |
| Pretax Income | -50.25B |
| Net Income | -50.45B |
| EBITDA | -21.81B |
| EBIT | -21.81B |
| Earnings Per Share (EPS) | -414.86 |
Balance Sheet
HLB Life Science Co Ltd holds 19.75B in cash and equivalents against 164.07B in total debt, resulting in a net debt position of 146.93B. Total book value stands at -29.78B, with working capital of -58.41B providing operational flexibility.
| Cash & Cash Equivalents | 19.75B |
| Total Debt | 164.07B |
| Net Debt | 146.93B |
| Equity (Book Value) | -29.78B |
| Book Value Per Share | -244.11 |
| Working Capital | -58.41B |
Cash Flow
HLB Life Science Co Ltd produced -23.49B in operating cash flow over the past twelve months. After subtracting -19.97B in capital expenditures, free cash flow totaled -43.47B - equivalent to -356.29 per share.
| Operating Cash Flow | -23.49B |
| Capital Expenditures | -19.97B |
| Free Cash Flow | -43.47B |
| FCF Per Share | -356.29 |
Margins
HLB Life Science Co Ltd operates with a gross margin of -2.81, reflecting its pricing power and cost economics. The operating margin of -42.33 and net profit margin of -97.94 provide insight into operational efficiency.
| Gross Margin | -2.81 |
| Operating Margin | -42.33 |
| Pretax Margin | -97.56 |
| Profit Margin | -97.94 |
| EBITDA Margin | -42.33 |
Stock Splits
HLB Life Science Co Ltd's most recent stock split took place on December 28, 2022 with a 500000:525849 split ratio.
| Last Split Date | 12/28/2022 |
| Split Ratio | 500000:525849 |
Scores
HLB Life Science Co Ltd posts an Altman Z-Score of -0.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.50 |